Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer

Stopped \<75% participation

Conditions

• Castration-Resistant Prostate Carcinoma
• Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents
• Metastatic Malignant Neoplasm in the Bone
• Metastatic Prostate Adenocarcinoma
• Metastatic Prostate Small Cell Neuroendocrine Carcinoma
• Stage IV Prostate Cancer AJCC v8
• Stage IVA Prostate Cancer AJCC v8
• Stage IVB Prostate Cancer AJCC v8

Interventions

• PROCEDURE: Biopsy
• PROCEDURE: Biospecimen Collection
• DRUG: Erdafitinib

Sponsor

M.D. Anderson Cancer Center